25ul each of CMVeGFP package with serotypes: 2/1, 2/2, 2/5, 2/6, 2/8, 2/9, 2/DJ, AAV2/6.2, 2/rh10, 2/PHP.B, 2/PHP.eB, 2/PHP.S.

The vectors are produced in human HEK293 cells.

The Viral Vector Core can produce rAAV via the Baculovirus system (Bac) in Sf9 insect cells from Robert Kotin or in transiently-transfected human HEK293 cells (3X). Vector production platforms have implications for vector binding, expression, trafficking, stability, and immunogenicity due to differences in post translational modifications. We recommend controls from the same system as custom vectors. Order human HEK293 (3X) controls if starting a new project or unsure.

References:

Paulk NK, et al. Methods Matter -- Standard Production Platforms For Recombinant AAV Can Produce Chemically And Functionally Distinct Vectors

https://europepmc.org/abstract/ppr/ppr79271

https://www.biorxiv.org/content/biorxiv/early/2019/05/17/640169.1.full.pdf

Urabe M., Ding C, and Kotin RM. Insect Cells as a Factory to Produce Adeno-Associated Virus. Type 2 Vectors HUMAN GENE THERAPY 13:1935–1943 (November 1, 2002)

https://www.liebertpub.com/doi/10.1089/10430340260355347

Smith RH, Levy JR, Kotin RM. A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther. 2009;17(11):1888–1896. doi:10.1038/mt.2009.128

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835045/

Kondratov, O. et al. Direct Head-to-Head Evaluation of Recombinant Adeno-associated Viral Vectors Manufactured in Human versus Insect Cells. Mol. Ther. 25, 2661–2675 (2017).

https://www.ncbi.nlm.nih.gov/pubmed/28890324

Giles, A. R. et al. Deamidation of Amino Acids on the Surface of Adeno-Associated Virus Capsids Leads to Charge Heterogeneity and Altered Vector Function. Mol. Ther. (2018). doi:10.1016/j.ymthe.2018.09.013

https://www.sciencedirect.com/science/article/pii/S1525001618304544?via%3Dihub

Ghaderi, D., Zhang, M., Hurtado-Ziola, N. & Varki, A. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol. Genet. Eng. Rev. 28, 147–175 (2012).

https://www.ncbi.nlm.nih.gov/pubmed/22616486

AAV2/2CMVeGFP